Characterisation and validation of biologically-driven HER2+ cancer subgroups in ALTTO and NeoALTTO

Dr Mattia Rediti, medical oncologist and PhD student at the Breast Cancer Translational Research Laboratory of the Institut Jules Bordet (ULB), presented a poster on the characterisation and validation of biologically-driven Her2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials.